MANNKIND CORP Payments to Acquire Held-to-maturity Securities
MANNKIND CORP (MNKD) reported Payments to Acquire Held-to-maturity Securities of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2026-02-26
- MANNKIND CORP payments to acquire held-to-maturity securities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- MANNKIND CORP payments to acquire held-to-maturity securities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- MANNKIND CORP payments to acquire held-to-maturity securities for the quarter ending 2024-09-30 was $86.34M, a 258.73% increase year-over-year.
- MANNKIND CORP payments to acquire held-to-maturity securities for the quarter ending 2024-06-30 was $119.05M.
- MANNKIND CORP payments to acquire held-to-maturity securities for fiscal 2024 was $273.79M, a 246.15% increase from fiscal 2023.
- MANNKIND CORP payments to acquire held-to-maturity securities for fiscal 2023 was $79.09M, a 6.12% increase from fiscal 2022.
- MANNKIND CORP payments to acquire held-to-maturity securities for fiscal 2022 was $74.54M, a 62.00% decline from fiscal 2021.
- MANNKIND CORP payments to acquire held-to-maturity securities for fiscal 2021 was $196.13M.
| Period end | Payments to Acquire Held-to-maturity Securities 3 month | Payments to Acquire Held-to-maturity Securities 6 month | Payments to Acquire Held-to-maturity Securities 9 month | Payments to Acquire Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $86.34M derived: sum of 3 quarters · filed 2026-02-26 | $205.39M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $86.34M derived: sum of 2 quarters · filed 2026-02-26 | $205.39M derived: sum of 3 quarters · filed 2026-02-26 | $273.79M 10-K · filed 2026-02-26 |
| 2024-09-30 | $86.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $205.39M derived: sum of 2 quarters · filed 2025-11-05 | $273.79M 10-Q · filed 2025-11-05 | $302.37M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $119.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $187.45M 10-Q · filed 2025-08-06 | $216.03M derived: sum of 3 quarters · filed 2026-02-26 | $240.09M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $68.40M 10-Q · filed 2025-05-08 | $96.98M derived: sum of 2 quarters · filed 2026-02-26 | $121.05M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $28.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $52.65M derived: sum of 2 quarters · filed 2026-02-26 | $79.09M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $24.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $50.52M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $26.45M 10-Q · filed 2024-08-07 | |||
| 2022-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $6.07M derived: sum of 2 quarters · filed 2025-02-26 | $18.55M derived: sum of 3 quarters · filed 2025-02-26 | $74.54M 10-K · filed 2025-02-26 |
| 2022-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $14.14M derived: sum of 2 quarters · filed 2023-11-07 | $70.13M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $12.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $68.47M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $55.99M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $196.13M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |